Pharmafile Logo
Pharmafocus logo
Advanced Search

bladder cancer

Showing 15 posts of 34 posts found.

Deadly cancers are being financially left behind, new research claims

May 1, 2025
Research and Development Jude, Oncology, UK, bladder cancer, cancer research, charitable funding

New research has revealed that some of the UK’s most deadly and prevalent cancers receive the least amount of charitable …

News

University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients

January 14, 2025
Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients

The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …

News

Johnson & Johnson receive MHRA approval for BALVERSA

November 8, 2024
Research and Development J&J Innovative Medicine, Oncology, Urology, bladder cancer

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment …

News

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024
Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology

Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …

News

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024
Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer

ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …

News

FDA approves Balversa for bladder cancer treatment

January 22, 2024
Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …

News

Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer

May 18, 2023
Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology

US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …

News

Birmingham University & Nonacus to develop urine test for bladder cancer

July 1, 2021
bladder cancer, cfdna, oncology

The University of Birmingham has partnered with Nonacus to develop a non-invasive test for bladder cancer. The test, which is …

News
Gilead sign

Gilead’s bladder cancer drug gets FDA approval

April 15, 2021
FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news

The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).

News
roche__tree

Roche voluntarily withdraws Tecentriq’s US bladder cancer indication

March 8, 2021
Sales and Marketing Cancer, Roche, bladder cancer, tecentriq

Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …

News
merck-keytruda

MSD’s Keytruda misses the mark at Phase 3 in advanced bladder cancer

June 11, 2020
Research and Development MSD< Keytruda, bladder cancer, pharma, trial failure

MSD has announced the disappointing findings that its anti-PD-1 immunotherapy Keytruda (pembrolizumab), when used either alone or combined with chemotherapy, …

News
az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

News
191209-f-kq373-1096

Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer

February 12, 2020
Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy

Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …

News
merck-keytruda

MSD’s Keytruda chalks up bladder cancer approval in the US

January 9, 2020
Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …

News
astellas_tokyo_copy_9

FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug

December 19, 2019
Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer

The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025